Get startedLog in
    Picture of BLS Pharmaceuticals logo

    BLS — BLS Pharmaceuticals News Story

    0.000.00%
    au flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapHigh Flyer
    All News

    Brief: Bioxyne Says FY25 Revenue Guidance Upgraded To A$28M

    Picture of BLS Pharmaceuticals logoBLS Pharmaceuticals
    12/06/2025 02:50
    June 12 (Reuters) - Bioxyne Ltd BXN.AX:

FULL YEAR FY2025 REVENUE GUIDANCE UPGRADED FROM A$25M TO A$28M.

EXPECTS CONTINUED GROWTH IN ITS AUSTRALIAN OPERATIONS IN FY2026.

REVENUE FOR H2 FY2025 IS EXPECTED TO BE A$15.4M

Further company coverage: BXN.AX

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on BLS Pharmaceuticals

    See all news